Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: A prospective, randomized and controlled trial

Giovanni B. Secco, Roberto Fardelli, Daniela Gianquinto, Pierfrancesco Bonfante, Eleonora Baldi, Giambattista Ravera, Lorenzo Derchi, Romano Ferraris

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: This paper aims to evaluate the diagnostic efficacy and costs of follow-up tailored according to risk of recurrence compared with minimal surveillance. Methods: A total of 358 patients treated by surgery alone for colorectal cancer were prospectively divided into two groups of 200 and 158 patients considered at high and low risk of recurrence respectively, according to prognostic factors. They were further randomized into two subgroups: group 1, 192 patients undergoing risk-adapted follow-up, intensive and low-intensity; group 2, 145 patients undergoing minimal surveillance. Twenty-one cases dropped out. Median follow-up was 61.5 months and 42 months for cases at high risk (intensive follow-up) and at low risk (low-intensity follow-up) respectively. Results: At the end of the study, 52.6% of patients undergoing risk-adapted follow-up and 57.2% undergoing minimal follow-up had developed recurrence. In patients at high risk, a significant difference in the incidence of curative re-operations was observed between the subgroups undergoing risk-adapted follow-up and subgroups undergoing minimal surveillance (P

Original languageEnglish
Pages (from-to)418-423
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume28
Issue number4
DOIs
Publication statusPublished - Jun 2002

Keywords

  • Cost-effectiveness
  • Curative re-operations
  • Intensive follow-up
  • Low-intensity follow-up
  • Minimal surveillance
  • Risk-adapted follow-up

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: A prospective, randomized and controlled trial'. Together they form a unique fingerprint.

Cite this